Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-80
SponsorScott Silveira
About this trial
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults.
The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels.
EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.
Eligibility criteria
Qualifiers
Adults aged 60 to 80 years, of any sex
Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing
Montreal Cognitive Assessment (MoCA) score of 26 or higher
Disqualifiers
Severe cardiovascular disease (e.g., recent myocardial infarction <6 months, unstable angina, uncontrolled hypertension >160/100 mmHg)
Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation)
Significant neurological impairments that hinder comprehension of instructions or participation in exercise
Terminal illness or conditions limiting life expectancy or ability to complete the study
Trial design
Treatments tested in this trial
- NMN, betaine, low-dose hydrogen peroxide (EGA)
- Nicotinamide Mononucleotide (NMN)
- Placebo
Treatment groups
40 Participants
are divided into 4 treatment groupsSponsors and collaborators
Scott Silveira
Lead sponsor
Concordia University Chicago
Sponsor institution
Concordia University Chicago
Collaborator
Source ClinicalTrials.gov